NCE Discovery and DARA Biosciences Join Forces to Develop New Therapies
Complete the form below to unlock access to ALL audio articles.
NCE Discovery Ltd. has entered into an agreement with US-based DARA BioSciences Inc. to work together on the development of new drug target molecules.
DARA BioSciences discovers and develops small molecule treatments for metabolic and CNS diseases and, under the terms of the agreement, will have access to NCED's full range of medicinal chemistry expertise, initially to address two specific drug targets.
"This collaboration is another prime example of NCE Discovery's successful operations as a service provider in the US pharmaceutical market," said Chris Sharman, NCED's CEO.
"We welcome the opportunity to work with the team at DARA BioSciences to speed up the discovery and development of important new medicines."
John Didsbury, Chief Scientific Officer at DARA BioSciences, commented: “We are looking forward to working with NCED and believe that the medicinal chemistry capabilities it brings to the collaboration will help tremendously with our development program of potential new therapies."
